Acute Coronary Syndromes
CVrg’s extensive coverage of Acute Coronary Syndromes, including the subindications ST-elevation MI (STEMI), non-ST-elevation MI (NSTEMI), and unstable angina (UA), provides breadth and depth of information to support our clients across a broad range of development and on-market activities.
Chung I ChoiSenior Director,
Cardiovascular & Atherosclerosis
Chung I received her B.A. from University of California, Berkeley in Biochemistry and Political Economics, and brings 20 years of biotechnology and pharmaceutical consulting experience to her clients. Her excellent communication skills, solid business acumen and command of analytical methods enable her to support a wide range of pharma teams. Chung I has directed CVrg’s atherosclerosis team since 2008.
Jennifer Lilla, Ph.D.
Therapy Area Director
Jennifer received her Ph.D. in Biomedical Sciences from the University of California, San Francisco and postdoctoral training at Stanford University’s School of Medicine before joining CVrg. In addition to her solid technical foundation, she brings strong analytic abilities and strategic planning experience as well as communication, writing and presentation skills to her leadership role on our thrombosis team.
| CVrg Market Strategies™ |
report
|
Acute Coronary Syndromes, 2019–2028 is a cutting-edge detailed market research report with unmatched scope, depth, and accuracy. This best-in-class resource provides a highly granular assessment of new product development, emerging trends, unmet needs, epidemiology, current treatment and market landscapes.
KOL comments, SWOTs, clinical trial tracking, estimations of launch dates and target patient populations are included for products ≥Ph 2 along with regional coverage of USA, EU5, and Japan. Fresh new data and analytical observations gained throughout the year in ACS from CVrg Sentinel, Conference, Insights and Advisory research are also included.
| CVrg Sentinel™ |
monthly updates
|
CVrg continuously monitors how new scientific, clinical, regulatory and market developments are changing the commercial potential of ACS assets. This monthly delivery informs clients about what is happening in the marketplace and how it might affect their products.
| CVrg Conference™ |
expert coverage
|
CVrg keeps abreast of cutting edge clinical data by attending cardio-metabolic congresses such as ACC, ESC and AHA. Our experts carefully analyze the new data presented and deliver incisive, presentation-style reports informing subscriber organizations about what’s new, what’s important, and why.
| *CVrg KOL Insights™ |
primary research
|
CVrg experts conduct primary research with KOLs in several disease areas, using their critical eyes to evaluate emerging trends, pipeline products and implications for the field. Clients may review and add to our “omnibus” discussion guides and receive detailed reports and presentations focused on answering the most pressing issues they face today. *Additional fees may apply.
| CVrg Advisory™ |
answers & new content
|
CVrg is uniquely positioned to deliver quick, thorough and reliable answers to non-proprietary questions in ACS drug markets. We are immediately equipped with comprehensive data and put our best methodologies and efforts behind each inquiry so clients receive the most accurate insight possible within a given timeframe.